早期乳腺癌患者一周超低分割局部区域放疗:急性毒性结果
该前瞻性登记研究纳入2020年7月至2023年9月276例早期乳腺癌患者,接受全乳或胸壁及同侧区域淋巴结26 Gy/5次一周超低分割放疗,中位随访19个月,57.6%报告急性不良事件,以G1为主,G3皮肤毒性14例,结论为耐受性良好。
要点
- 276例早期乳腺癌接受26 Gy/5次一周超低分割局部区域放疗,中位随访19个月。
- 57.6%报告急性不良事件,G1为50.4%、G2为7.8%,皮肤G3毒性14例。
- 随访超过6个月的213例中无臂丛神经病或G3毒性。
核心结论
- 一周超低分割辅助局部区域放疗耐受性良好,毒性谱与其他类似照射方案研究相当。
研究设计与样本
- 前瞻性登记分析,2020年7月至2023年9月纳入276例早期乳腺癌患者。
- 全乳放疗占58.3%,胸壁放疗占41.7%,均联合同侧区域淋巴结照射及同步整合补量(58.3%)。
- 放疗方案为26 Gy分5次,一周内完成。
- 主要终点为急性不良事件评估,次要终点为早期延迟毒性发生情况。
- 要求至少6个月随访以评估治疗相关早期延迟并发症,采用CTCAE v5.0标准评估。
主要发现
- 中位随访19个月(范围1-49个月),159例(57.6%)报告不良事件,其中G1为139例(50.4%)、G2为20例(7.8%)。
- 皮肤急性毒性常见,G1/2共134例,G3共14例。
- 乳腺水肿10例(G1为9例,G2为1例),乳腺疼痛占15.9%(G1为42例,G2为2例)。
- 同侧手臂水肿发生率为1.8%。
- 随访超过6个月的213例患者中,23.4%报告G1/G2皮肤不良事件,8.8%出现G1/G2乳腺/胸壁水肿,8.9%发生手臂淋巴水肿,该组无臂丛神经病或G3毒性病例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Moderate hypofractionated radiotherapy is the standard of care for all patients with breast cancer, irrespective of stage or prior treatments. While extreme hypofractionation is accepted for early-stage tumours, its application in irradiating locoregional lymph nodes remains controversial. MATERIALS AND METHODS: A prospective registry analysis from July 2020 to September 2023 included 276 patients with early-stage breast cancer treated with one-week ultra-hypofractionation (UHF) at 26 Gy in 5 fractions on the whole breast (58.3 %) or thoracic wall (41.7 %) and ipsilateral regional lymph nodes and simultaneous integrated boost (58.3 %). Primary endpoint was assessment of acute adverse events (AEs). Secondarily, onset of early-delayed toxicity was assessed. A minimum 6-month follow-up was required for assessing potential treatment-related early-delayed complications. Acute or late complications attributable to treatment were assessed at inclusion using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 criteria. RESULTS: With a median follow-up of 19 months (range 1-49 months), 159 (57.6 %) patients reported AEs, predominantly grade (G) 1 (n = 139, 50.4 %) and G2 (n = 20, 7.8 %). Skin acute toxicity was common (G1/2: 134, G3: 14), while breast oedema occurred in 10 patients (G1: 9, G2: 1), and 15.9 % reported breast pain (G1: 42, G2: 2). Ipsilateral arm oedema was observed in 1.8 % patients. For patients with a follow-up beyond 6 months (n = 213), 23.4 % patients reported G1/G2 skin AEs, 8.8 % had G1/G2 breast/chest wall oedema, and 8.9 % experienced arm lymphedema. There were no cases of brachial plexopathy or G3 toxicity in this group of patients. CONCLUSIONS: One-week UHF adjuvant locoregional radiation is well-tolerated, displaying low-toxicity profiles comparable to other studies using similar irradiation schedules.
引用
- Ratosa I, Montero A, Ciervide R, et al. Ultra-hypofractionated one-week locoregional radiotherapy for patients with early breast cancer: Acute toxicity results. Clin Transl Radiat Oncol. 2024. PMID: 38516338. doi:10.1016/j.ctro.2024.100764
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。